Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:THRM
NasdaqGS:THRMAuto Components

Why Gentherm (THRM) Is Up 8.5% After Soft Q4 Profit But Strong 2026–2027 Revenue Outlook

In February 2026, Gentherm reported fourth‑quarter 2025 earnings showing net income falling to US$2.99 million from US$15.32 million a year earlier, while quarterly revenue of about US$382.79 million came in ahead of expectations. Alongside weaker profitability, Gentherm issued product revenue guidance of US$1.5 billion to US$1.6 billion for 2026 and US$1.7 billion for 2027, highlighting its ambition to grow beyond automotive into medical and other precision thermal applications. We’ll now...
NasdaqGS:ATRO
NasdaqGS:ATROAerospace & Defense

Is It Too Late To Consider Astronics (ATRO) After A 298% One Year Rally?

If you are looking at Astronics and wondering whether the recent excitement lines up with the underlying value, this article is going to walk through the key numbers that matter for you. The stock last closed at US$79.39, with returns of 3.1% over 7 days, 4.0% over 30 days, 40.2% year to date and 297.7% over the past year. The 3 year and 5 year returns are 420.9% and 409.6% respectively. These returns sit against a backdrop of ongoing news flow around Astronics' role in the capital goods...
XTRA:RWE
XTRA:RWERenewable Energy

How RWE’s Norfolk Vanguard West Turbine Deal and KKR Partnership Will Impact RWE (XTRA:RWE) Investors

RWE has recently placed a firm order with Vestas for 92 V236-15.0 MW turbines for the 1,380 MW Norfolk Vanguard West offshore wind project in the UK, following its successful award of a Contract for Difference in Allocation Round 7 and targeting final investment decision in summer 2026 with commissioning in 2029. This contract, alongside KKR acquiring a 50% stake in the Norfolk Vanguard projects, underscores how RWE is advancing capital-light partnerships to expand its offshore wind...
NYSE:APH
NYSE:APHElectronic

Evaluating Amphenol (APH) After Strong Q4 Earnings Beat And Upbeat Guidance

Why Amphenol’s latest earnings are drawing fresh attention Amphenol (APH) is back in focus after reporting Q4 results that exceeded analyst expectations on both revenue and profitability, along with guidance for the next quarter that also came in ahead of forecasts. The company closed 2025 with record Q4 and full year sales, as well as adjusted diluted EPS that management said were significantly above the high end of prior guidance. This highlighted strong demand across its connector and...
NYSE:KR
NYSE:KRConsumer Retailing

Kroger (KR) Valuation Check As New CEO Greg Foran Takes Over And Cost Cuts Accelerate

Kroger (KR) has drawn fresh attention after appointing former Walmart executive Greg Foran as CEO, following an ethics related departure. The company is pressing ahead with cost cuts, corporate restructuring, and selective store and fulfillment center closures. See our latest analysis for Kroger. Those management changes and cost initiatives sit against a share price of US$69.76, with a 30 day share price return of 8.6% and a 5 year total shareholder return of 138.3%, suggesting longer term...
TSX:IMO
TSX:IMOOil and Gas

Imperial Oil (TSX:IMO) Valuation Check After Strong Recent Share Price Momentum

Why Imperial Oil Is On Investors’ Radar Today Imperial Oil (TSX:IMO) has drawn attention after a strong run in recent periods, with the share price showing double digit total returns over the past year and solid gains year to date. See our latest analysis for Imperial Oil. At around CA$158.23, Imperial Oil’s recent 30 day share price return of 14.2% and year to date gain of 29.37% suggest momentum has been building. Its one year total shareholder return of 65.79% and very large five year...
NYSE:WWW
NYSE:WWWLuxury

Is Wolverine World Wide (WWW) Pricing Lagging Its Recent Share Price Recovery

If you are wondering whether Wolverine World Wide at around US$17.58 is offering real value or just looks cheap on the surface, you are not alone. The stock has pulled back over the short term, with a 2.9% decline over 7 days and a 2.4% decline over 30 days, yet it still shows a 19.7% return over 1 year and 14.4% over 3 years, compared with a 42.3% decline over 5 years. Recent attention on Wolverine World Wide has focused on its long term share price pattern. The stronger 1 year and 3 year...
TSX:MG
TSX:MGAuto Components

Assessing Magna International (TSX:MG) Valuation After Softer Earnings Guidance And Dividend Increase

Why Magna’s latest earnings, guidance and dividend move matter now Magna International (TSX:MG) just paired softer fourth quarter profitability with fresh 2026 sales guidance of US$41.9b to US$43.5b, a higher quarterly dividend, and updates on its ongoing share repurchase activity. See our latest analysis for Magna International. The mixed earnings picture, firmer 2026 sales guidance and another dividend increase have arrived after a 22.18% 30 day share price return and a 70.88% 1 year total...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

Why GeneDx Holdings (WGS) Is Down 11.3% After Reaffirming 2026 Guidance And Narrowing 2025 Losses

In February 2026, GeneDx Holdings Corp. reported full-year 2025 results showing revenue of US$427.54 million versus US$305.45 million in 2024, alongside a narrower net loss of US$21.02 million and reduced basic loss per share from continuing operations of US$0.73 compared with US$1.94 a year earlier. At the same time, GeneDx reaffirmed its 2026 revenue outlook of US$540 million to US$555 million and highlighted FDA Breakthrough Device Designation plus a near-tripling of its sales force as it...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

A Look At Jazz Pharmaceuticals (JAZZ) Valuation After 2025 Results And 2026 Revenue Guidance

Why Jazz Pharmaceuticals' latest earnings matter for shareholders Jazz Pharmaceuticals (JAZZ) has become a focus for investors after reporting fourth quarter and full year 2025 results, alongside 2026 revenue guidance, combining stronger quarterly earnings with a full year net loss profile. For the fourth quarter of 2025, Jazz Pharmaceuticals reported revenue of US$1,197.93 million compared with US$1,088.17 million a year earlier, while net income was US$203.45 million compared with US$191.12...
NYSE:DOCN
NYSE:DOCNIT

DigitalOcean Holdings DOCN One Off Gain Lifts Margins And Tests Bullish Narratives

DigitalOcean Holdings FY 2025 Earnings Snapshot DigitalOcean Holdings (DOCN) has wrapped up FY 2025 with Q4 revenue of US$242.4 million and basic EPS of US$0.28, capping off a year in which trailing twelve month revenue reached US$901.4 million and EPS came in at US$2.83. The company has seen revenue move from US$780.6 million to US$901.4 million on a trailing twelve month basis, while EPS shifted from US$0.92 to US$2.83, with reported earnings growth helped by a very large year over year...
NasdaqGS:ZM
NasdaqGS:ZMSoftware

Zoom Virtual Agent 3.0 Aims To Deepen Zoom Enterprise AI Role

Zoom Communications (NasdaqGS:ZM) has launched Zoom Virtual Agent 3.0, a new version of its AI-powered customer service tool. The update introduces broader automation capabilities for handling complex customer interactions and proactive outreach for enterprise clients. Zoom Virtual Agent 3.0 is positioned as part of Zoom's broader push into AI-driven products beyond its core video conferencing offering. For you as an investor, this move aligns with Zoom Communications' core identity as a...
NYSE:NEM
NYSE:NEMMetals and Mining

Newmont Balances Record 2025 Cash Returns With Rising Operational Risks

Newmont (NYSE:NEM) reports record earnings and free cash flow for 2025 and updates its capital allocation plan. The company raises its dividend, outlines a framework for disciplined shareholder returns, and completes major operational milestones, including commercial production at Ahafo North and integration of key Newcrest assets. Newmont also discloses operational setbacks, including a safety incident at Tanami and production challenges at Nevada Gold Mines, and issues a default notice to...
NasdaqCM:NEO
NasdaqCM:NEOHealthcare

Is NeoGenomics’ (NEO) RaDaR ST Medicare Win Quietly Redefining Its Oncology Diagnostics Edge?

Earlier in February 2026, NeoGenomics launched RaDaR ST, a high-sensitivity circulating tumor DNA assay for molecular residual disease detection, supported by Medicare approval for initial indications and backed by clinical and real-world data across select cancers. The company also introduced PanTracer Pro to streamline complex molecular testing workflows and reported higher quarterly sales with a smaller net loss, highlighting growing adoption of newer, higher-value oncology...
NYSE:SCL
NYSE:SCLChemicals

Stepan’s Project Catalyst Overhaul Puts Valuation Discount In Sharper Focus

Stepan Company (NYSE:SCL) has launched Project Catalyst, a multi year operational and efficiency overhaul. The program targets $100 million in projected savings through plant closures and asset decommissions. Several global facilities are expected to be affected as Stepan reshapes its manufacturing footprint. Stepan is a specialty chemicals producer serving markets such as surfactants, polymers, and specialty products, areas that often face swings in demand and input costs. Project Catalyst...
NYSE:TPR
NYSE:TPRLuxury

Assessing Tapestry (TPR) Valuation After Upgraded 2026 Outlook And Strong Brand Momentum

Tapestry (TPR) recently raised its fiscal 2026 outlook, guiding to revenues above US$7.75b and EPS growth of 25%. This shift has sharpened investor focus on what is driving the stock. See our latest analysis for Tapestry. Tapestry's recent outlook upgrade sits alongside a strong share price run, with a 30 day share price return of 18.82% and a 1 year total shareholder return of 86.84% suggesting momentum has been building rather than fading. If this kind of momentum has you thinking about...
ASX:WTC
ASX:WTCSoftware

WiseTech Global’s AI Overhaul And Job Cuts Test Long Term Thesis

WiseTech Global (ASX:WTC) plans to cut nearly 30% of its workforce over the next two years. The reduction is part of a CEO led shift toward AI driven operations across the business. The move is framed as a structural transformation of WiseTech Global's cost base and operating model. WiseTech Global, a logistics software group known for its CargoWise platform, sits at the intersection of global trade, freight forwarding, and supply chain management. The push toward AI comes as logistics...
NYSE:IEX
NYSE:IEXMachinery

Assessing IDEX (IEX) Valuation After Recent Share Price Momentum And Mott Acquisition Integration

Why IDEX (IEX) is on investors’ radar today IDEX (IEX) is drawing attention after a period of steady share price movement, with recent returns and current valuation metrics prompting investors to reassess how the company’s fundamentals line up with its current price. See our latest analysis for IDEX. At a share price of $208.45, IDEX has seen steady momentum recently, with a 30-day share price return of 6.75% and a 90-day share price return of 19.96%. The 1-year total shareholder return of...
ASX:360
ASX:360Software

Life360 (ASX:360) Valuation Check After Expanded Uber Partnership And Slower Recent Share Price Momentum

Life360 (ASX:360) is back in focus after Uber expanded its partnership with the family safety app by introducing account linking, real-time trip tracking, and ride booking for parents and teens within the Life360 ecosystem. See our latest analysis for Life360. The Uber announcement lands after a weak patch in Life360’s trading, with a 30-day share price return of 31.75% and a 90-day share price return of 41.46% compared with a very large 5-year total shareholder return. This suggests longer...
NasdaqGS:BRKR
NasdaqGS:BRKRLife Sciences

Is Bruker (BRKR) Now Attractive After A 21% One Year Share Price Decline?

If you are wondering whether Bruker is priced attractively right now, you are not alone, especially with sentiment around the stock shifting recently. The share price closed at US$39.77, with a 4.3% gain over the last 7 days, set against returns of a 21.0% decline over 30 days, a 17.3% decline year to date, and a 21.6% decline over 1 year, as well as 41.7% and 35.1% declines over 3 and 5 years respectively. These mixed shorter term and longer term returns have put more attention on what...
NYSE:O
NYSE:ORetail REITs

Realty Income (O) Valuation Check After Recent Share Price Momentum And Spirit Merger Impact

Why Realty Income is on investors’ radar today Realty Income (O) is drawing fresh interest after recent share price moves, with the stock last closing at $66.52. For income focused investors, that prompts a closer look at its current profile. See our latest analysis for Realty Income. Recent moves fit into a stronger run, with a 30-day share price return of 9.52% and a 90-day share price return of 16.42%, while the 1-year total shareholder return of 25.07% points to building momentum around...
NasdaqGS:MNDY
NasdaqGS:MNDYSoftware

What monday.com (MNDY)'s Analyst Downgrades and Rising Scrutiny Mean For Shareholders

In recent days, Jefferies downgraded monday.com from Buy to Hold, and several other analysts also reassessed their views on the company, signaling increased caution about its near-term prospects. This shift in analyst sentiment highlights growing scrutiny of monday.com's execution risks, competitive positioning, and the sustainability of its growth-focused business model. We’ll now examine how this broad reset in analyst sentiment could reshape monday.com’s investment narrative and its...
NasdaqGS:TENB
NasdaqGS:TENBSoftware

Tenable Holdings (TENB) Is Down 17.2% After Tariff Hike And AI Security Jitters - Has The Bull Case Changed?

Earlier this week, Tenable Holdings, a cybersecurity and vulnerability management provider, came under pressure after the White House announced plans to lift global tariffs to 15%, sparking renewed concern about trade policy and its knock-on effects for technology and software firms. At the same time, investors are weighing Tenable’s ongoing profitability and liquidity challenges against sector worries that rapid advances in artificial intelligence could reshape demand for traditional...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

Does TG Therapeutics (TGTX) Offer Value After Recent Share Price Swings

If you are wondering whether TG Therapeutics at around US$30.51 is priced attractively or already baking in a lot of optimism, you are in the right place. The stock has returned 5.0% over the last 7 days, is down 2.2% over 30 days, and shows mixed longer term results with a 4.2% return year to date, 4.5% over 1 year, 90.4% over 3 years, and a 32.0% decline over 5 years. These moves sit against a backdrop of ongoing interest in TG Therapeutics as a biotechnology name, with investors watching...